Trial Profile
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer, With or Without PI3K Activated Pathway.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Dactolisib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Apr 2022 This trial has been completed in Spain according to the European Clinical Trials Database record
- 05 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
- 28 Mar 2012 Additional trial location (France) added as reported by ClinicalTrials.gov.